688108 Sino Medical Sciences Technology Inc.
- 9.13
- -0.10-1.08%
Sino Medical Sciences Technology Inc. News
Sino Medical Sciences Technology Board Elects Chairman
The board of Sino Medical Sciences Technology (SHA:688108) elected Sun Jianhua as chairman of the board. The chair has a term of three years, according to a Friday filing with the bourse.
China Approves Sino Medical's Intracranial Stent System
China approved Sino Medical Sciences Technology (SHA:688108) subsidiary Sino Medical Science and Technology's product registration for a self-expanding intracranial drug-eluting stent system. The devi
Sano Medical (688108.SH): Subsidiary's self-inflating intracranial drug-coated stent system application for domestic medical device registration was accepted
On May 28, Ge Longhui Medical (688108.SH) announced that the self-inflating intracranial drug coating stent system independently developed by the company's subsidiary Sano Shenchang Medical Technology Co., Ltd. (“Sano Shenchang” or “subsidiary”) submitted a medical device registration application to the State Drug Administration in May 2024. The State Drug Administration recently issued a “Notice of Acceptance” to the company. Expected use: The self-inflating intracranial drug coating stent system is used for intracranial atherosclerotic stenosis. It supports and opens the stenosis and obstructed lumen, improves intracranial artery lumen diameter, and improves brain tissue ischemia
Sano Healthcare (688108.SH): Currently, the business mainly covers key areas of interventional treatment such as cardiovascular, cerebrovascular, and structural heart diseases
Gelonghui, May 10 | Sano Healthcare (688108.SH) said on the investor interactive platform that the company is an international company rooted in China, targeting the global market, and focusing on R&D, production and sales of high-end interventional medical devices. Currently, the company's business mainly covers key areas of interventional treatment such as cardiovascular, cerebrovascular, and structural heart diseases.
Sino Medical Sciences Technology Inc. (SHSE:688108) Surges 13%; Retail Investors Who Own 41% Shares Profited Along With Insiders
Key Insights Significant control over Sino Medical Sciences Technology by retail investors implies that the general public has more power to influence management and governance-related decisions The
Sano Healthcare (688108.SH) reported 2023 annual results with a net loss of 39.63 million yuan
Sano Healthcare (688108.SH) released its 2023 annual report. The company achieved operating income of 3 during the reporting period...
Sano Healthcare (688108.SH): Product obtained registration certificate in Belarus
On April 18, GLONGHUI (688108.SH) announced that in December 2023, the company submitted registration data for the company's HT SupremeTM drug-eluting stents, NCROCKSTARTM non-compliant balloon dilatation catheters, and SC HONKYTONKTM coronary balloon dilation catheters to the Ministry of Health of Belarus (“MOH” for short). The company recently received a notice from MOH, the company HT SupremeTM drug-eluting stents, NC ROCKSTART non-compliant balloon expansion catheter, SC HONK
Sano Healthcare (688108.SH): The company's products obtained a registration certificate in Korea
On March 15, GLONGHUI (688108.SH) announced that in November 2022 and May 2023, the company submitted registration data for the company's HTSUPremetM drug-eluting stent, NCROCKSTART non-compliant balloon dilatation catheter, and SCHONKYTONKTM coronary balloon dilation catheter to the Korean Ministry of Food and Drug Safety (hereinafter referred to as “MFDS”), respectively. The company recently received an MFDS notification that the company HTSUPremetM drug-eluting stents and NCROCKSTARTM non-compliant balloon dilatation
There's Reason For Concern Over Sino Medical Sciences Technology Inc.'s (SHSE:688108) Massive 41% Price Jump
Sino Medical Sciences Technology Inc. (SHSE:688108) shareholders are no doubt pleased to see that the share price has bounced 41% in the last month, although it is still struggling to make up recently
Sano Healthcare (688108.SH): The company's products obtained a registration certificate in Pakistan
On March 5, GLONGHUI (688108.SH) announced that in May 2023, the company submitted registration data for the company SC HONKYTONKTM coronary balloon dilation catheter and NC ROCKSTART non-compliant balloon dilatation catheter to the Pakistan Drug Administration (“DRAP”). The company recently received DRAP notice, and the company SC HONKYTONKTM coronary balloon dilation catheter and NC ROCKSTART non-compliant balloon dilatation catheter were approved by DRAP
Sano Healthcare (688108.SH): HT Supreme drug-eluting stent system obtained registration certificate in Hong Kong, China
Sano Healthcare (688108.SH) announced that in September 2022, the company told the Medical Device Division of the Hong Kong Department of Health, China...
Sano Healthcare (688108.SH): The company's products obtained a registration certificate in Hong Kong, China
On March 4, Ge Longhui Medical (688108.SH) announced that the company submitted registration information for the company's HT Supreme drug-eluting stent system to the Medical Device Division of the Hong Kong Department of Health (hereinafter referred to as “MDD”) in September 2022. The company recently received a notice from MDD, and the company's HT Supreme drug-eluting stent system was approved by MDD. The HT SupremeTM drug-coated coronary stent system is suitable for improving coronary artery disease in patients with symptomatic heart disease due to the primary coronary artery lesion site (length ≤ 40 mm)
Southwest Securities: There is still a lot of room for penetration in the coronary artery disease interventional treatment market, focus on Sano Healthcare (688108.SH), etc.
Coronary heart disease is the leading cause of death in the world, and there is still plenty of room for penetration in the interventional treatment market for coronary artery disease in China.
Is Sino Medical Sciences Technology (SHSE:688108) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved whe
Sino Medical Sciences Technology's Unit Gets Certificate for Catheter
Sino Medical Sciences Technology's (SHA:688108) unit, Sano Shenchang Medical Technology, received a medical device registration certificate from China's National Medical Products Administration for a
Sano Healthcare (688108.SH): Pre-loss of 47 million yuan to 57 million yuan in 2023
Gelonghui, January 29丨Sano Healthcare (688108.SH) announced its 2023 annual results forecast. According to preliminary estimates by the finance department, the revenue for the reporting period is expected to be 337 million yuan to 345 million yuan, an increase of 144.15 million yuan to 152.15 million yuan over the same period last year, an increase of 75% to 79% over the previous year. During the reporting period, net profit attributable to shareholders of listed companies is expected to reduce losses significantly compared to the same period last year: net profit attributable to shareholders of listed companies is expected to be -57 million yuan to -47 million yuan, an increase of 10,538 over the same period last year
Sino Medical Sciences Technology's HT Supreme Stent System Enters Bangladeshi Market
Sino Medical Sciences Technology (SHA:688108) will be able to market the HT Supreme drug-eluting stent system in Bangladesh after receiving a registration certificate from the country's drug regulator
Sano Healthcare (688108.SH): HT Supreme drug-eluting stent system obtained registration certificate in Bangladesh
Gelonghui, January 9, 丨 Sano Healthcare (688108.SH) announced that in July 2022, the company submitted registration information for the company's HT Supreme drug-eluting stent system to the Bangladesh Drug Administration (hereinafter referred to as “DGDA”). The company recently received a notice from DGDA, and the company's HT Supreme drug-eluting stent system was approved by DGDA. The HT Supreme drug-eluting stent system approved by DGDA this time is a new type of drug stent production developed based on the “healing window” theory pioneered by our company
Sino Medical Sciences Technology Inc.'s (SHSE:688108) Popularity With Investors Is Under Threat From Overpricing
With a price-to-sales (or "P/S") ratio of 16.6x Sino Medical Sciences Technology Inc. (SHSE:688108) may be sending very bearish signals at the moment, given that almost half of all the Medical Equipme
Sano Healthcare (688108.SH): The controlling shareholder and some shareholding platforms intend to agree to transfer part of the shares and provide all of the proceeds to the company for free use
Gelonghui (688108.SH) announced on December 13|Sano Healthcare () announced that the controlling shareholders of Sano Medical Science and Technology Co., Ltd. “Weixin Sunshine,” “Sunshine Foundation,” “Sunshine Enterprise,” and “Sunshine Jiaye” signed a “Share Transfer Agreement” with Guo Yanchao. They intend to transfer a total of 20,500,000 shares of Sano Healthcare's shares to Guo Yanchao through an agreement transfer at a price of 9.78 yuan/share. After the transfer of this agreement is completed, “Weixin Sunshine” still directly holds 71,859,417 shares of the listed company, accounting for 17.5267% of the company's total shares, and is still a competition
Analysis
Price Target
No Data
